candidaemia or invasive candidiasis in patients with neutropenia are largely obtained from pooled outcomes of randomised trials, 13 and from subsets of trials that included relatively small numbers of patients with neutropenia. [14] [15] [16] Based on these limited results, the Infectious Diseases Society of America guidelines for the treatment of candidiasis recommend either an echinocandin or lipid formulations of amphotericin B (AmB) for most patients with neutropenia and concurrent candidiasis. 17 The European Society of Clinical
Microbiology and Infectious Disease guidelines strongly recommend micafungin or caspofungin for targeted treatment of candidaemia and/or invasive candidiasis in patients with malignancies, with anidulafungin or liposomal amphotericin B (L-AmB) mentioned as alternatives. 18 Micafungin is an echinocandin that is better tolerated than L-AmB, has a similar safety profile to caspofungin and fluconazole, 19 and is licensed for use in both adult and paediatric patients in Europe, 20 the United States 21 and other countries. However, there are currently no studies directly comparing the treatment outcomes of micafungin for invasive candidiasis in patients with and without neutropenia.
Therefore, we conducted a pooled, post hoc analysis of 2 Phase 3 trials that investigated micafungin for the treatment in candidaemia or invasive candidiasis 17, 22, 23 to evaluate its efficacy in patients with neutropenia. The effect of duration of neutropenia on outcomes was also examined.
| METHODS

| Study design and patients
Details of the 2 Phase 3 studies of micafungin for the treatment of candidaemia or invasive candidiasis have been published elsewhere. [22] [23] [24] Briefly, 1 study compared the treatment with micafungin 100 mg/d 
| Study definitions
Efficacy was assessed in all patients with neutropenia at baseline (absolute neutrophil count [ANC] at baseline of <500 cells/μL) who had confirmed candidaemia or a confirmed invasive fungal infection and who received ≥1 dose of micafungin. If no ANC value was available, a white blood cell count of <500 cells/μL was used. Efficacy was also assessed as a function of the pathogen isolated at baseline in patients with and without neutropenia.
Effects of the duration of neutropenia on outcomes were assessed by stratifying patient data as follows: neutropenia ≥1 day included all patients with baseline neutropenia; neutropenia ≥8 days included all patients who were neutropenic at baseline, in treatment for at least 3 | RESULTS
| Patient characteristics
A total of 685 patients (adult = 637 and paediatric = 48) were included in this analysis of whom 77 (including 6 paediatric patients) had neutropenia at baseline ( Table 1 ). The majority (85%; n/N = 582/685) of patients had candidaemia, whereas 15% (n/N = 102/685) had invasive candidiasis; 1 patient was diagnosed with non-Candida invasive fungal infection. C. tropicalis was the most common infecting Candida spp. in patients with neutropenia, whereas infection with C. albicans was most common in patients without neutropenia. For patients with neutropenia, haematological malignancy without transplant was the most common underlying condition. Overall, 19 (24.7%) and 2 (0.3%) patients with and without neutropenia at baseline, respectively, had HSCT.
| Efficacy
Overall mortality in patients with neutropenia at baseline was numerically higher throughout the study period and significantly higher at Day 28 ( Table 2) . A smaller proportion of patients with vs without neutropenia were deemed an overall treatment success Overall treatment success, clinical success and mycological success were significantly higher in patients whose neutropenia resolved compared to those in which neutropenia persisted (Table 3) . When assessed by pathogen, a similar pattern of lower response rates in patients with vs without neutropenia was almost uniformly apparent across spp. (Table 4 ).
| DISCUSSION
The primary objective of this pooled analysis was to add to the lim- However, it was noted in this study that micafungin was associated with more breakthrough infections than caspofungin (3/48, 27.3% vs 0/82, 0%). In a pooled analysis with a smaller number of patients with neutropenia and invasive candidiasis (n = 27), 14 caspofungin achieved an overall success rate in 17/27 (63%) in those patients and mortality was observed to be 37% by day 14. The mortality rate in the current analysis was observed to by 40.5% by Day 28. In a pooled analysis of 539 patients with invasive candidiasis treated with anidulafungin, 46 patients with neutropenia were identified. 26 The overall successful response at the end of intravenous therapy was lower in patients with neutropenia compared to the global population as a whole (26/46, 56.5% vs 412/539, 76.4% respectively).
Persistence of neutropenia has long been identified as a risk factor for poorer outcomes in candidiasis. [27] [28] [29] The results of this study confirm this, with poorer overall treatment response, clinical response and mycological response observed in patients whose neutropenia at baseline resolved, compared to patients who still had neutropenia at EOT.
In the current analysis C. tropicalis was the most common infecting Candida spp. in patients with neutropenia. This is consistent with previous observations regarding the frequency and virulence of C. tropicalis in patients with neutropenia. 30 In contrast, C. albicans was more commonly observed in patients without neutropenia and overall in the population of the Phase 3 micafungin studies. 22, 23 C. albicans may be the most common Candida spp. that infects patients with solid organ transplants and haematological malignancy, although it is likely to account for less than half of all Candida infections. 11 In fact, a multivariate analysis found that patients with neutropenia were at a higher T A B L E 4 Efficacy results in patients with neutropenia for ≥1 day and patients without neutropenia by Candida spp (mITT population) risk of non-albicans Candida spp. infections, 11 and at least 1 previous study has found that C. tropicalis infection is associated with severe neutropenia and HSCT. 31 The small number of patients and retrospective nature of the analysis pose obvious limitations. Moreover, limitations of each of the contributing studies would also apply. 22, 23 Nevertheless, the analysis contributes further evidence for the efficacy of micafungin, and echinocandins as a whole, in patients with neutropenia. This is especially important given the high medical need for effective antifungal treatment in this group of patients.
| CONCLUSIONS
